Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows strong financial performance with expected revenue growth, improved margins, and strategic investments. The Q&A section highlights positive analyst sentiment, particularly regarding Phase III trials and AI initiatives. While some details on new products and services are vague, the overall outlook is optimistic with expected revenue growth, strategic partnerships, and margin improvements. The company's focus on expanding its global supply chain and the positive sentiment from analysts suggest a favorable stock price movement in the near term.
Key Financial Performance
Revenue $47.8 million, up 16% year-over-year. This growth is attributed to momentum across integrated services and products platform.
Revenue from commercial cell and gene therapy $9.1 million, up 26% year-over-year. Growth driven by support for the industry's broadest cell and gene therapy pipelines.
Revenue from clinical trials $12.9 million, up 18% year-over-year. Growth attributed to leadership across commercial and clinical programs.
Life Sciences Services segment revenue Increased 18% year-over-year, including 21% growth in BioStorage/BioServices. Growth reflects increasing adaptation of full service portfolio and complexity of cell therapy programs.
Life Sciences Products segment revenue Increased 15% year-over-year. Growth driven by global demand for MVE Biological Solutions cryogenic systems.
Adjusted EBITDA from continuing operations Improved by $2.2 million year-over-year. Improvement driven by growth across reporting segments, solid gross margins, and operational discipline.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revenue from commercial cell and gene therapy: Grew 26% to $9.1 million in Q1 2026.
Revenue from clinical trials: Increased 18% to $12.9 million in Q1 2026.
New product launch: MVE introduced the Fusion 800 series, a self-sustaining cryogenic freezer eliminating the need for continuous liquid nitrogen supply, targeting space-constrained environments.
Global clinical trials supported: Increased to 766, a net rise of 55 trials year-over-year, with 91 in Phase III.
Commercial therapies supported: Increased to 21 with the FDA approval of Rocket Pharmaceutical's gene therapy, KRESLADI.
Future therapy approvals: Expecting up to 8 additional new therapy approvals and 10 BLA or MAA application filings in 2026.
Revenue growth in Life Sciences Services: Increased 18% year-over-year, including 21% growth in BioStorage/BioServices.
Revenue growth in Life Sciences Products: Grew 15% driven by global demand for MVE Biological Solutions cryogenic systems.
Operational efficiency: Achieved a $2.2 million year-over-year improvement in adjusted EBITDA from continuing operations.
IntegriCell milestone: Shipped first cryopreserved clinical trial patient materials from facilities in Houston, Texas, and Belgium.
Digital and AI initiatives: Implemented generative AI tools to automate tasks, analyze data, manage risk, and improve operational efficiency.
Strategic partnership with DHL: Sale of CRYOPDP to DHL in June 2025, with financials now presented as discontinued operations.
Revenue guidance for 2026: Raised to $192 million to $196 million, with expectations of achieving positive adjusted EBITDA in the second half of 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company is exposed to regulatory risks, as highlighted by the mention of FDA approvals and the dependency on regulatory bodies for therapy approvals. Any delays or rejections in regulatory processes could adversely impact operations and revenue.
Strategic Execution Risks: The company is heavily reliant on its strategic partnerships, such as the one with DHL Group, and the successful execution of its digital and AI initiatives. Failure in these areas could hinder operational efficiency and growth.
Market Dependency: The company's growth is tied to the success of the cell and gene therapy market, including clinical trials and therapy approvals. Any downturn or slower-than-expected growth in this market could negatively affect revenue.
Supply Chain Challenges: The company’s operations depend on the availability and reliability of cryogenic systems and supply chain services. Disruptions in these areas could impact service delivery and client satisfaction.
Economic Uncertainties: Broader economic conditions could influence the company’s financial performance, particularly in terms of demand for its services and products.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for FY 2026: Cryoport has raised its full-year 2026 revenue guidance to a range of $192 million to $196 million, reflecting increased visibility into the remainder of the year.
Adjusted EBITDA: The company expects to achieve positive adjusted EBITDA in the second half of 2026.
Commercial Therapies Support: Cryoport anticipates supporting up to 8 additional new therapy approvals and 10 BLA or MAA application filings for the remainder of 2026.
Market Expansion with New Product: The introduction of the Fusion 800 series cryogenic freezer is expected to open new markets previously inaccessible, contributing to long-term growth.
Digital and AI Strategy: Cryoport is advancing its digital and AI initiatives to improve operational efficiency, automate tasks, and accelerate decision-making, which is expected to play an increasingly important role in the company's future.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Program: The presentation did not mention any specific dividend program or plans to distribute dividends to shareholders.
Share Buyback Program: The presentation did not mention any specific share buyback program or plans to repurchase shares.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why did the company raise its guidance by only $2 million despite a $3 million beat versus consensus?
A:The company believes the guidance is responsible given the continued uncertainty on a global macroeconomic basis. They will continue to evaluate and adjust guidance quarterly if warranted.
Q:What is the expected growth for Life Science product MVE, and what factors are driving this growth?
A:The company expects high single-digit growth for Life Science product MVE, driven by strong demand across all geographies, particularly in animal health and life sciences. MVE is the market leader in cryogenic systems worldwide.
Q:Is the company seeing momentum from improved biotech funding for RFP volumes or contract volumes?
A:Yes, the company is seeing continued investment into Phase II and Phase III programs, with Phase III trials increasing by 5 sequentially and Phase II programs up by almost 30 year-over-year. This indicates positive signs from the funding environment.
Q:What are the initial learnings and expectations for IntegriCell in 2026?
A:The company is pleased with the rollout of IntegriCell, which supports clinical processes in Belgium and Houston. It is expected to be a long-term driver for revenue and margin expansion, with onboarding taking 12-18 months. The fully integrated service platform has been well received.
Q:What are the assumptions for achieving positive EBITDA in the second half of the year?
A:The company expects positive EBITDA in the second half of the year, driven by revenue growth and operating leverage from investments in new facilities. These facilities will enhance profitability and adjusted EBITDA in 2026 and beyond.
Q:How durable are the company's AI initiatives in reducing operational expenses?
A:The AI initiatives are durable and focused on enhancing internal efficiency and effectiveness. They are practical tools aimed at improving operations and are expected to reshape the business over time.
Q:What is the status and impact of the new supply chain centers in Paris and Santa Ana?
A:The Paris site is operational for biologistics, with bioservices to be added in Q3. The Santa Ana site consolidates three locations into one, offering expanded services. Revenue contribution from these centers will be smaller in 2026 but significant in 2027.
Q:What is the expected growth rate for commercial cell and gene therapy revenue in 2026?
A:The company expects strong growth for commercial cell and gene therapy revenue in 2026, driven by existing commercial therapies. New approvals may contribute, but the guidance is based on the current platform.
Q:How many commercial products is the company supporting, and what is the potential for new launches?
A:The company is supporting 21 commercial products and expects 8 potential new approvals in the next 12 months, with 5 already having PDUFA dates.
Q:What is the difference in revenue potential and margins between commercial and clinical trial products?
A:Commercial products have higher revenue potential as they are used globally for patients, unlike clinical trial products limited to specific trials. Revenue increases with patient population and expanded services.
Q:What factors contributed to the company's strong revenue growth this quarter?
A:Revenue growth was driven by increased demand across all revenue streams, including bioservices and products. The normalization of demand in the second half of 2025 also contributed to the strong performance.
Q:Is the commercial acceleration concentrated in CAR-T therapies, and what is the outlook for cell and gene therapies?
A:The majority of commercial customers are cell therapies, with CAR-T therapies leading the growth. Gene therapies have had a slower start, but cell therapies are driving the market.
Q:What is the pipeline status for the Fusion 800 series?
A:The Fusion 800 series is in the early stages, with distributors showing excitement. It is too early to comment on the pipeline.
Q:Has the momentum from moving patients out of hospitals to ambulatory centers continued?
A:Yes, the momentum has continued, with outpatient and community hospital growth driving revenue for companies like J&J and Bristol.
Q:What factors affected MVE product margins this quarter?
A:MVE product margins were affected by specific product mix rather than energy prices or pricing erosion.
Q:What is the impact of increased biotech funding on customer activity and sentiment?
A:Increased biotech funding has positively impacted customer activity and sentiment, particularly for smaller companies needing funding. The company sees strong funding as beneficial for the industry.
Q:How does the company handle inflationary pressures on pricing?
A:The company passes on fuel surcharges to clients in transportation and logistics, and has not seen significant impact from increased prices on the product side.
Q:What is the expected growth rate for the products business in 2026?
A:The company expects high single-digit growth for the products business in 2026, driven by solid global demand.
Q:What is the outlook for IntegriCell's contribution to the company?
A:IntegriCell is expected to be an important contributor in the future, with a good start and gaining attention. It takes time for integrated services to take effect.
Q:Review of Unclear Management Responses
A:The company avoided providing specific details about the pipeline for the Fusion 800 series, stating it was too early to comment. Additionally, they did not provide precise revenue or margin expectations for IntegriCell, citing the early stages of its rollout.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CRYOPDP DHL
CRYOPDP financials
Communications obligation
Exchange Commission
Factors Form
Fusion series
MVE Fusion
Securities Exchange
date information
dividend year
document
engineering feat
environment source
example MVE
feat dividend
feed reliability
floor example
footprint space
freezer need
host KCSA
need nitrogen
nitrogen engineering
nitrogen supply
reliability safety
review
safety sustainability
segment figure
self freezer
series self
source nitrogen
space environment
statement Kanan
supply feed
sustainability footprint
year market
CYRX Transcript
Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call summary shows strong financial performance with expected revenue growth, improved margins, and strategic investments. The Q&A section highlights positive analyst sentiment, particularly regarding Phase III trials and AI initiatives. While some details on new products and services are vague, the overall outlook is optimistic with expected revenue growth, strategic partnerships, and margin improvements. The company's focus on expanding its global supply chain and the positive sentiment from analysts suggest a favorable stock price movement in the near term.
Cryoport, Inc. (CYRX) Q4 2025 Earnings Call Transcript
Unknown3-3
Despite strategic initiatives and partnerships, Cryoport faces challenges with a 5% revenue decline and reduced gross margins. Improved guidance and strategic partnerships may not offset current financial weaknesses, leading to a likely negative stock reaction.
Cryoport, Inc. (CYRX) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call highlights reaffirmed revenue guidance for 2025 and a strong outlook for commercial revenue growth, supported by FDA approvals. The strategic partnership with DHL is expected to enhance capabilities, and there is optimism for regulatory approvals. While there are some uncertainties, such as the gene therapy pause and lack of profitability guidance for 2026, the overall sentiment is positive, particularly with the potential for market expansion and strategic initiatives. The Q&A session further supports this with positive analyst sentiment and no significant concerns about market exits.
Cryoport, Inc. (CYRX) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call summary and Q&A reflect a generally positive outlook. The strategic partnership with DHL, strong demand in clinical trials, and positive customer feedback indicate growth potential. Gross margins are stable, and the company's strategic focus on Life Sciences and new product launches are promising. Although there are uncertainties like the impact of FDA's REMS update and competitive dynamics, the overall sentiment is optimistic, supported by robust financial metrics and strategic initiatives. The positive response to being more carrier-agnostic post-DHL transaction further strengthens the outlook.
CYRX Slides
CYRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
